

***Election of chairman of the Meeting (item 1)***

The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Håkan Björklund (chairman of the Board of Directors), Petra Hedengran, chairman (Investor AB), Lennart Francke (Swedbank Robur Fonder AB) and Thomas Ehlin (Fjärde AP-fonden (AP4)), proposes that Eva Hägg from Mannheimer Swartling Advokatbyrå is elected chairman of the Meeting.

***Fees for the members of the Board of Directors and the auditor (item 10)***

The Nomination Committee proposes the following:

- that fees to be paid to the Board of Directors should be SEK 1,575,000 to the chairman of the Board of Directors and SEK 515,000 to each of the other members of the Board of Directors elected by the Annual General Meeting, that fees for work in the Audit Committee should be SEK 175,000 to the chairman and SEK 105,000 to each other member of such committee, that fees for work in the Compensation & Benefits Committee should be SEK 115,000 to the chairman and SEK 65,000 to each other member of such committee and that fees for work in the Science Committee should be SEK 115,000 to the chairman and SEK 65,000 to each other member of such committee,
- that, in addition to the fees proposed above, for each physical meeting of the Board of Directors held in Sweden, a meeting fee of SEK 10,000 is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a meeting fee of USD 3,000 is paid to the members of the Board of Directors that reside outside Europe, and
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice.

***The number of members of the Board of Directors, deputy members, auditors and deputy auditors (item 11)***

The Nomination Committee proposes the following:

- that eight ordinary members of the Board of Directors without deputies should be appointed, and
- that one auditor without any deputy auditor should be appointed.

***Election of the chairman, the members of the Board of Directors and the auditor (item 12)***

The Nomination Committee proposes the following:

- that Håkan Björklund, Annette Clancy, Matthew Gantz, Helena Saxon, Staffan Schüberg and Elisabeth Svanberg should be re-elected as ordinary members of the Board of Directors, that Filippa Stenberg and Anders Ullman should be elected as new ordinary members of the Board of Directors and that Håkan Björklund should be re-elected as chairman of the Board of Directors, and
- that Ernst & Young AB should be re-elected as auditor of the company until the end of the Annual General Meeting 2022, in accordance with the Audit Committee's recommendation.

#### *Filippa Stenberg*

Filippa Stenberg (born 1985) has a M.Sc. in economics from Stockholm School of Economics.

Ms. Stenberg is Investment Manager at Investor AB. She has previously worked as an analyst at Swedbank LC&I.

#### *Anders Ullman*

Anders Ullman (born 1956) has a MD-PhD in Clinical Pharmacology.

Dr. Ullman is a member of the board of directors of Verona Pharma plc. He was the Head of the COPD center at the Sahlgrenska University Hospital 2015-2020. He has more than 20 years of experience from several executive positions within research and development in the international pharmaceutical industry, including AstraZeneca, Bayer Pharmaceuticals, Biovitrum, Nycomed/Takeda and Baxter Bioscience.

#### *The Nomination Committee recommends the elected board members to build their own holdings of shares in the company*

Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holding, are expected to, over a five year period, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.